BlackThorn Therapeutics, Inc.

SAN DIEGO, Feb. 20, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the "IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072, and pending it the Southern District of New York, the Neumora class action lawsuit charges Neumora as well as certain of Neumora's top executives and directors, and certain underwriters of the IPO, with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Neumora class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Neumora is a clinical-stage biopharmaceutical company that engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. According to the complaint, Neumora acquired Navacaprant, Neumora's flagship therapeutic candidate, in September 2020 through its acquisition of BlackThorn Therapeutics, Inc. In its IPO, Neumora sold 14.7 million shares at $17.00 per share. The Neumora class action lawsuit alleges that the IPO's offering documents were materially false and/or misleading and/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (ii) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (iii) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. The Neumora class action lawsuit further alleges that on January 2, 2025, Neumora revealed that the KOASTAL-1 study failed to "demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale." Since the IPO, the value of Neumora common stock shares has declined substantially from the IPO price of $17 per share to a closing price of $1.91 per share on February 5, 2025 (a 88.7% decline from the IPO price), the complaint alleges. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Neumora common stock pursuant and/or traceable to the registration statement issued in connection with the IPO to seek appointment as lead plaintiff in the Neumora class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Neumora class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Neumora class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Neumora class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] SOURCE Robbins Geller Rudman & Dowd LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the "IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072 (S.D.N.Y.), the Neumora class action lawsuit charges Neumora and certain of Neumora's top executives and directors, as well as certain underwriters of the IPO, with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Neumora class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Neumora is a clinical-stage biopharmaceutical company that engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. According to the complaint, Neumora acquired Navacaprant, Neumora's flagship therapeutic candidate, in September 2020 through its acquisition of BlackThorn Therapeutics, Inc. In its IPO, Neumora sold 14.7 million shares at $17.00 per share. The Neumora class action lawsuit alleges that the IPO's offering documents were materially false and/or misleading and/or failed to disclose that: (i) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ("MDD") to show that Navacaprant offered a statistically significant improvement in treating MDD; (ii) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (iii) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. The Neumora class action lawsuit further alleges that on January 2, 2025, Neumora revealed that the KOASTAL-1 study failed to "demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale." Since the IPO, the value of Neumora common stock shares has declined substantially from the IPO price of $17 per share to a closing price of $1.91 per share on February 5, 2025 (a 88.7% decline from the IPO price), the complaint alleges. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Neumora common stock pursuant and/or traceable to the registration statement issued in connection with the IPO to seek appointment as lead plaintiff in the Neumora class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Neumora class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Neumora class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Neumora class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] SOURCE Robbins Geller Rudman & Dowd LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials for its experimental major depression drug, saying Thursday that navacaprant was not statistically significant at improving patients’ depressive symptoms better than placebo in the late-stage KOASTAL-1 trial. Neumora is hoping to compete against Johnson & Johnson, which is also running Phase 3 studies for its experimental MDD drug, called aticaprant, and markets the esketamine spray Spravato. Both companies are developing kappa opioid receptor (KOR) antagonists, which are meant to hit upon the reward processing and dopamine pathways. The biotech’s stock price $NMRA fell 80% in Thursday morning trading in reaction to the news. In the 383-adult KOASTAL-1, navacaprant and placebo both led to a -12.5 change from baseline on the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS). “We are disappointed by the results from KOASTAL-1 as they were not consistent with the body of evidence supporting this mechanism in MDD,” Neumora head of R&D Rob Lenz said in a statement. “There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in depressed mood and anhedonia in female participants compared to male participants.” Neumora CEO Henry Gosebruch said the company will share more details on its pipeline at the JP Morgan Healthcare Conference later this month. The first results for Neumora’s once-daily pill are a preview of more to come. The company is running two additional identical pivotal trials dubbed KOASTAL-2 and KOASTAL-3. Those trials are expected to read out in the first half of this year, the company has said. In their note from December, Stifel analysts said Neumora’s drug likely only needs to succeed in two of the trials. “The other two would likely have sufficient data for an NDA as the psychiatry division typically doesn’t penalize sponsors for a negative study,” the analysts wrote Dec. 16. If navacaprant makes it to market for major depression, the analysts predict almost $3 billion in peak worldwide revenues. The readout also marks a key moment for the KOR space. J&J is expected to release Phase 3 data for aticaprant this year. If either company is successful, it will open up a new treatment option in depression, a large market that has lacked effective new treatments and run into clinical or regulatory disappointments . The opportunity is so large that ARCH Venture Partners named Neumora the “ Really Big Neuroscience Company ” when it formed the startup. The company attracted key industry leaders to its management team, including Gosebruch , the former AbbVie strategy chief. It then went public in a $250 million IPO in September 2023. While Gosebruch was at AbbVie, the drug giant got a label expansion in depression for its drug Vraylar. In prior studies, navacaprant helped patients with moderate-to-severe MDD in a Phase 2 trial, but it didn’t hit statistical significance in the overall study population when factoring in mildly depressed patients. Neumora did not include mildly depressed patients in its Phase 3. BlackThorn Therapeutics, which designed the Phase 2 trial, was acquired by Neumora in 2020. Editor’s note: This story was updated to include stock price reaction.